Phase 2 N=118 Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients
Histoplasmosis · AIDS
Primary: Clinical Response — 32; 25; 28 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 2 N=219 Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis
Cryptococcal Meningitis
Primary: Early Fungicidal Activity — 0.39; 0.28 log10 CFU/mL/day
Phase 3 N=16 POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
Coccidioidomycosis
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events (TRAEs) That Occurred With Posaconazole (POS) or Fluconazole (FLU) in Period A — 5; 3…
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Phase 3 N=88 Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
Invasive Fungal Infections
Primary: Comparison of Plasma Itraconazole Levels and Hydroxyitraconazole Levels at Day 14 — 60.5; 71.0 percentage of participants
N/A N=249 Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 Respiratory Infection · Aspergillosis
Primary: Incidence of COVID-19 Associated Pulmonary Aspergillosis (CAPA) — 1.69; 0.84; 7.18 Cases per 1000 ICU days
Phase 2 N=143 Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
Cryptococcal Meningitis
Primary: Number of Grade 3-5 Adverse Experiences That Are Definitely or Probably Related to Study Drug — 2; 1; 0; 0 Events